IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir

Gastroenterology. 2017 Dec;153(6):1694-1695. doi: 10.1053/j.gastro.2017.06.069. Epub 2017 Nov 3.

Authors

Thomas R O'Brien¹, Shyam Kottilil², Ruth M Pfeiffer³

Affiliations

¹ Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
² Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
³ Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Intramural

MeSH terms

Aminoisobutyric Acids
Carbamates / administration & dosage*
Cyclopropanes
Drug Combinations
Genotype
Hepacivirus / drug effects*
Hepatitis C, Chronic / drug therapy
Hepatitis C, Chronic / genetics*
Hepatitis C, Chronic / virology
Heterocyclic Compounds, 4 or More Rings / administration & dosage*
Humans
Interleukins / analysis*
Lactams, Macrocyclic
Leucine / analogs & derivatives
Macrocyclic Compounds / administration & dosage*
Proline / analogs & derivatives
Quinoxalines
Recurrence
Sofosbuvir / administration & dosage*
Sulfonamides / administration & dosage*
Sustained Virologic Response

Substances

Aminoisobutyric Acids
Carbamates
Cyclopropanes
Drug Combinations
Heterocyclic Compounds, 4 or More Rings
IFNL4 protein, human
Interleukins
Lactams, Macrocyclic
Macrocyclic Compounds
Quinoxalines
Sulfonamides
sofosbuvir-velpatasvir drug combination
voxilaprevir
Proline
Leucine
Sofosbuvir

Grants and funding

Z01 CP005782/ImNIH/Intramural NIH HHS/United States